Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data

Abstract

We aimed to identify and compare medication profiles in populations with polypharmacy between 2005 and 2015. We conducted a cross-sectional study using information from the Computerized Database for Pharmacoepidemiologic Studies in Primary Care (BIFAP, Spain). We estimated the prevalence of therapeutic subgroups in all individuals 15 years of age and older with polypharmacy (≥5 drugs during ≥6 months) using the Anatomical Therapeutic Chemical classification system level 4, by sex and age group, for both calendar years. The most prescribed drugs were proton-pump inhibitors (PPIs), statins, antiplatelet agents, benzodiazepine derivatives, and angiotensin-converting enzyme inhibitors. The greatest increases between 2005 and 2015 were observed in PPIs, statins, other antidepressants, and β-blockers, while the prevalence of antiepileptics was almost tripled. We observed increases in psychotropic drugs in women and cardiovascular medications in men. By patient´s age groups, there were notable increases in antipsychotics, antidepressants, and antiepileptics (15–44 years); antidepressants, PPIs, and selective β-blockers (45–64 years); selective β-blockers, biguanides, PPIs, and statins (65–79 years); and in statins, selective β-blockers, and PPIs (80 years and older). Our results revealed important increases in the use of specific therapeutic subgroups, like PPIs, statins, and psychotropic drugs, highlighting opportunities to design and implement strategies to analyze such prescriptions’ appropriateness.

Medical Psychotropics in Forensic Autopsies in European Countries: Results from a Three-Year Retrospective Study in Spain

“…In addition to this situation, the phenomenon of polypharmacy among psychotropic users makes the study of the determinants and importance of these drugs from a medicolegal perspective more complex. Polypharmacy, defined as the combination of several psychotropics drugs [20], is a very worrying phenomenon because it could be associated with an additional burden of adverse effects [21,22]. In this regard, the increasing rate of combined use of MOs and BZDs is of particular concern and is considered a major public health problem in the United States and in most developed countries [23,24].…”

Multimorbidity Clusters in the Oldest Old: Results from the EpiChron Cohort

“…It is logical to think that some combinations of diseases may have a higher impact on health than others and that pharmacological management plays a vital role in clinical outcomes. The high mean number of diseases and drugs in older adults may involve disease–disease, drug–drug, and drug–disease interactions, as well as prescribing cascades [ 68 , 69 ], increasing the risk of potentially inappropriate medication and its clinical consequences [ 70 , 71 , 72 ]. An interesting finding, for example, was the high use of drugs with anticholinergic activity in clusters with dementia, especially in octogenarians and nonagenarians.…”

LESS-PHARMA Study: Identifying and Deprescribing Potentially Inappropriate Medication in the Elderly Population with Excessive Polypharmacy in Primary Care

“…Polypharmacy and the concurrent use of potentially inappropriate medications have become more prevalent. Elderly patients and patients with multiple chronic conditions are at a higher risk of having multiple prescriptions [ 1 , 2 ]. Pharmacological treatment is one of the most common medical interventions in many diseases, along with surgical treatment and lifestyle modifications.…”